Investors

Growing Shareholder Value

Press Releases

Abiomed’s Response to the COVID-19 Pandemic

Mar 25, 2020
Read More
Additional Formats
PDF Version

Study of 21,848 High-Risk PCI Patients Demonstrates Lower Risk of Death and Complications in Patients who Receive PVADs (Impella)

Mar 04, 2020
Read More

Abiomed Announces Q3 FY 2020 Revenue of $222 Million and 31.7% Operating Margin

Feb 06, 2020
Read More
Additional Formats
PDF Version

Abiomed Announces Preliminary Q3 FY 2020 Revenue of $222 Million, up 10% Over Prior Year

Jan 13, 2020
Read More
Additional Formats
PDF Version

Abiomed to Present at the 38th Annual J.P. Morgan Healthcare Conference

Dec 30, 2019
Read More
Additional Formats
PDF Version

First Patient Enrolls in STEMI DTU Randomized Controlled FDA Trial; Study Aims to Further Demonstrate Impella’s Safety and Effectiveness

Dec 16, 2019
Read More
Additional Formats
PDF Version

Abiomed to Present at the 31st Annual Piper Jaffray Healthcare Conference

Nov 27, 2019
Read More
Additional Formats
PDF Version

Abiomed Medical Office Completes Review of Observational Analysis of Impella Presented at AHA

Nov 19, 2019
Read More
Additional Formats
PDF Version

Clinical Review Demonstrates Cost-Effectiveness of Impella in High-Risk PCI and Cardiogenic Shock

Nov 14, 2019
Read More
Additional Formats
PDF Version

First U.S. Patients Treated with Impella 5.5 with SmartAssist, a Minimally Invasive, Forward Flow Heart Pump

Oct 31, 2019
Read More
Additional Formats
PDF Version
View all